|Survival benefit of eribulin mesylate in heavily pretreated metastatic breast cancer: What next?|Aftimos, P.; Awada, A. (2011). Survival benefit of eribulin mesylate in heavily pretreated metastatic breast cancer: What next? Adv. Ther. 28(11): 973-985. dx.doi.org/10.1007/s12325-011-0070-9
In: Advances in Therapy. Springer: Tarporley. ISSN 0741-238X, more
anthracyclines; capecitabine; clinical trials; eribulin mesylate;metastatic breast cancer; microtubules; taxanes
|Authors|| || Top |
Eribulin is a synthetic analog of halichondrin B, a non-taxane microtubule inhibitor extracted from the marine sponge, Halichondria okaida. It presents a novel mechanism of action and is active on cancer cells resistant to other antimicrotubule agents. It was granted approval in the USA and Europe for the treatment of heavily pretreated metastatic breast cancer. Early trials had shown activity in this setting with main toxicities being neutropenia and neuropathy in patients where quality of life is essential. Approvals were granted after a phase 3 trial demonstrated overall survival benefit in metastatic breast cancer previously treated with anthracyclines, taxanes, and capecitabine, in a setting where most treatments are failing to demonstrate a survival benefit. Recent data suggest that this survival benefit is also consistent in the elderly with no excess toxicity. Future strategies of eribulin are being tested in ongoing trials, evaluating this drug in earlier metastatic lines as well as in the adjuvant and the neoadjuvant settings.